Human Monocytic Leukemia Cell Line

U.S. Patent 5,804,443  [See PDF or HTML]

Abstract

The present invention comprises a novel, immortal human monocytic leukemia cell line, designated MC-1010. This cell line has been demonstrated to induce an immune response when injected into non-human primates. This leukemic cell line is also a source of a unique ATPase that is found in only low levels in normal human cells. The immortal nature of the MC-1010 cell line allows it to be used as the replicative fusion partner for making hybridomas and also makes it an excellent source of enzymes (e.g., telomerase) and other cellular components involved in the cellular replication process.

This cell line is available from American Type Culture Collection
Catalog No. CRL-12253

MC-1010 cells are made available to the research and development community; neither royalties nor other form of payment have ever been received or requested.  Please consult the patent for details of cell propagation.  The following organizations have purchased this cell line from ATCC:
Ohio State Universtiy
Human Cancer Genetics
Columbus, Ohio		 Stanford University
Palo Alto, California
Emory University
Decatur, Georgia		 Minneapolis Medical Research Foundation
Minneapolis, Minnesota
Bio-Technology General, Israel
Rehovot, Israel		 Scripps Research Institute
La Jolla, California
Ohio State University
Research Foundation
Columbus, Ohio		 National Institutes of Health
Advanced Technology Center
Gaithersburg, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts		 Baxter Labs
Round Lake, Illinois
VWR Scientific
Morrisville, North Carolina		 Genome Research
Wellcome Trust Genome Campus
Cambridge, England
Sepracor, Inc.
Marlborough, Massachusetts		 Massachusetts General Hospital
Charlestown, Massachusetts
References
  1. Informing Report, 10/21/1998 to 12/31/2002, American Type Culture Collection, Manassas, VA.

  2. Informing Report, 01/01/2013 to 01/31/2013, American Type Culture Collection, Manassas, VA.

FREE RADICALS AND CANCER
BERNOFSKY CURRICULUM VITAE